These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 6441959)

  • 1. Clinical trials with the cholinergic drug RS 86 in Alzheimer's disease (AD) and senile dementia of the Alzheimer type (SDAT).
    Wettstein A; Spiegel R
    Psychopharmacology (Berl); 1984; 84(4):572-3. PubMed ID: 6441959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RS 86 in the treatment of Alzheimer's disease: cognitive and biological effects.
    Hollander E; Davidson M; Mohs RC; Horvath TB; Davis BM; Zemishlany Z; Davis KL
    Biol Psychiatry; 1987 Sep; 22(9):1067-78. PubMed ID: 3651528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No response to high-dose muscarinic agonist therapy in Alzheimer's disease.
    Mouradian MM; Mohr E; Williams JA; Chase TN
    Neurology; 1988 Apr; 38(4):606-8. PubMed ID: 3281057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscarinic agonist therapy of Alzheimer's disease. A clinical trial of RS-86.
    Bruno G; Mohr E; Gillespie M; Fedio P; Chase TN
    Arch Neurol; 1986 Jul; 43(7):659-61. PubMed ID: 3524514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholinergic approaches to the treatment of Alzheimer's disease.
    Hollander E; Mohs RC; Davis KL
    Br Med Bull; 1986 Jan; 42(1):97-100. PubMed ID: 3006861
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of a cholinomimetic drug (RS 86) in tardive dyskinesia and drug-related parkinsonism.
    Noring U; Povlsen UJ; Casey DE; Gerlach J
    Psychopharmacology (Berl); 1984; 84(4):569-71. PubMed ID: 6152058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muscarinic agonists for senile dementia: past experience and future trends.
    Gray JA; Enz A; Spiegel R
    Trends Pharmacol Sci; 1989 Dec; Suppl():85-8. PubMed ID: 2694530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of oral physostigmine in primary degenerative dementia. A double-blind study of response to different dose level.
    Beller SA; Overall JE; Swann AC
    Psychopharmacology (Berl); 1985; 87(2):147-51. PubMed ID: 3931138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer's disease. A critical review.
    Gottfries CG
    Compr Gerontol C; 1988 Dec; 2(1):47-62. PubMed ID: 3076510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of cholinergic drug effects on memory in Alzheimer's disease.
    Brinkman SD; Gershon S
    Neurobiol Aging; 1983; 4(2):139-45. PubMed ID: 6355883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study.
    Saletu B; Paulus E; Linzmayer L; Anderer P; Semlitsch HV; Grünberger J; Wicke L; Neuhold A; Podreka I
    Psychopharmacology (Berl); 1995 Feb; 117(4):385-95. PubMed ID: 7604138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia.
    Christie JE; Shering A; Ferguson J; Glen AI
    Br J Psychiatry; 1981 Jan; 138():46-50. PubMed ID: 7023592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's disease and senile dementia of Alzheimer type. A comparative study.
    Sulkava R
    Acta Neurol Scand; 1982 Jun; 65(6):636-50. PubMed ID: 7113668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep.
    Foster NL; Aldrich MS; Bluemlein L; White RF; Berent S
    Neurology; 1989 Feb; 39(2 Pt 1):257-61. PubMed ID: 2644580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cholinergic agonist RS 86: a pharmacopsychological study.
    Fritze J; Beckmann H
    Neuropsychobiology; 1988; 19(1):35-9. PubMed ID: 3054624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholinergic strategies in the treatment of Alzheimer's disease.
    Davidson M; Stern RG; Bierer LM; Horvath TB; Zemishlani Z; Markofsky R; Mohs RC
    Acta Psychiatr Scand Suppl; 1991; 366():47-51. PubMed ID: 1897375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physostigmine effects in Alzheimer's disease: relationship to dementia severity.
    Schwartz AS; Kohlstaedt EV
    Life Sci; 1986 Mar; 38(11):1021-8. PubMed ID: 3512944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A comparative study on histopathological findings between Alzheimer's disease and senile dementia of Alzheimer type].
    Nakamura N
    Rinsho Byori; 1996 Mar; 44(3):225-30. PubMed ID: 8857164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of long-term continuous infusion of the muscarinic cholinergic agonist arecoline on verbal memory in dementia of the Alzheimer type.
    Raffaele KC; Berardi A; Asthana S; Morris P; Haxby JV; Soncrant TT
    Psychopharmacol Bull; 1991; 27(3):315-9. PubMed ID: 1775605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dementia of the Alzheimer type and multi-infarct dementia: a clinical description and diagnostic problems.
    Bucht G; Adolfsson R; Winblad B
    J Am Geriatr Soc; 1984 Jul; 32(7):491-8. PubMed ID: 6203954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.